23:58:22 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande



2025-02-20 Bokslutskommuniké 2024
2024-11-21 Kvartalsrapport 2024-Q3
2024-08-28 Kvartalsrapport 2024-Q2
2024-05-16 Ordinarie utdelning LIDDS 0.00 SEK
2024-05-15 Årsstämma 2024
2024-05-15 Kvartalsrapport 2024-Q1
2024-02-27 Extra Bolagsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2023-11-28 Kvartalsrapport 2023-Q3
2023-08-30 Kvartalsrapport 2023-Q2
2023-05-30 Ordinarie utdelning LIDDS 0.00 SEK
2023-05-29 Kvartalsrapport 2023-Q1
2023-05-29 Årsstämma 2023
2023-03-13 Bokslutskommuniké 2022
2023-01-09 Extra Bolagsstämma 2022
2022-11-28 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-06-02 Ordinarie utdelning LIDDS 0.00 SEK
2022-06-01 Årsstämma 2022
2022-05-24 Kvartalsrapport 2022-Q1
2022-02-23 Bokslutskommuniké 2021
2021-11-22 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-18 Kvartalsrapport 2021-Q1
2021-05-18 Ordinarie utdelning LIDDS 0.00 SEK
2021-05-17 Årsstämma 2021
2021-02-25 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-15 Ordinarie utdelning LIDDS 0.00 SEK
2020-05-14 Kvartalsrapport 2020-Q1
2020-05-14 Årsstämma 2020
2020-02-27 Bokslutskommuniké 2019
2019-11-28 Kvartalsrapport 2019-Q3
2019-08-29 Kvartalsrapport 2019-Q2
2019-05-17 Ordinarie utdelning LIDDS 0.00 SEK
2019-05-16 Kvartalsrapport 2019-Q1
2019-05-16 Årsstämma 2019
2019-02-28 Bokslutskommuniké 2018
2018-11-29 Kvartalsrapport 2018-Q3
2018-08-30 Kvartalsrapport 2018-Q2
2018-05-17 Ordinarie utdelning LIDDS 0.00 SEK
2018-05-16 Kvartalsrapport 2018-Q1
2018-05-16 Årsstämma 2018
2018-02-22 Bokslutskommuniké 2017
2017-11-09 Kvartalsrapport 2017-Q3
2017-10-06 Extra Bolagsstämma 2017
2017-08-31 Kvartalsrapport 2017-Q2
2017-05-12 Ordinarie utdelning LIDDS 0.00 SEK
2017-05-11 Årsstämma 2017
2017-05-11 Kvartalsrapport 2017-Q1
2017-02-23 Bokslutskommuniké 2016
2016-10-27 Kvartalsrapport 2016-Q3
2016-08-24 Kvartalsrapport 2016-Q2
2016-06-09 Extra Bolagsstämma 2016
2016-04-22 Årsstämma 2016
2016-04-22 Kvartalsrapport 2016-Q1
2016-04-21 Ordinarie utdelning LIDDS 0.00 SEK
2016-02-10 Bokslutskommuniké 2015
2015-10-29 Kvartalsrapport 2015-Q3
2015-08-13 Kvartalsrapport 2015-Q2
2015-04-22 Ordinarie utdelning LIDDS 0.00 SEK
2015-04-21 Årsstämma 2015
2015-04-21 Kvartalsrapport 2015-Q1
2015-02-20 Bokslutskommuniké 2014
2014-11-11 Kvartalsrapport 2014-Q3
2014-08-21 Kvartalsrapport 2014-Q2


ListaFirst North Stockholm
LIDDS är ett läkemedelsbolag. Bolaget utvecklar läkemedelsprodukter baserade på en patentskyddad och kliniskt testad drug delivery-teknologi. Egenskaperna hos produkterna utgör grunden för LIDDS teknologiplattform för utveckling av injicerbara läkemedelsprodukter. LIDDS är förkortningen för Local Intelligent Drug Delivery System och bolaget har sitt huvudkontor i Uppsala.
2023-11-28 09:30:00

July – September 2023

  • Net sales amounted to 0 (1.2) MSEK
  • The operating result for the period was -4.5 (-8.1) MSEK
  • The net result was -4.5 (-8.1) MSEK corresponding to earnings per share of SEK -0.07 (-0.24)
  • Cash flow from operating activities amounted to -5.5 (-7.3) MSEK
  • Cash and cash equivalents amounted to 17.1 (14.9) MSEK

January – September 2023

  • Net sales amounted to 0 (2.0) MSEK
  • The operating result for the period was -21.5 (-27.7) MSEK
  • The net result was -21.5 (-27.7) MSEK corresponding to earnings per share of SEK -0.35 (-0.81)
  • Cash flow from operating activities amounted to -22.7 (-25.4) MSEK

Significant events January – September

  • The rights issue was approved at an EGM in January, 2023 and was completed in February 2023. Approximately 72.7 percent of the rights issue, were subscribed for. The bottom guarantors were allocated approx 8.6 percent of the rights issue, and the top guarantors approx 14.4 percent of the rights issue. The company received approximately SEK 46.5 million before issue costs. Three of the guarantors chose compensation in the form of shares.
  • The company implements significant cost containment measures to maximize the possibility of reaching a license agreement without the need for further financing. The decision means that further investments in clinical development will be held back until licensing agreements can be secured. Staff reductions have been implemented and Anders Månsson left the CEO role in August 2023. The board appointed Matthew Lindon as acting CEO.
  • Max Mitteregger resigns from the Board of Directors
  • The collaboration agreement with Johnson & Johnson Enterprise Innovation Inc is closed.

Events after the reporting period

  • Jenni Björnulfson is being appointed CEO.

CEO Statement
The focus for LIDDS in the third quarter was to complete on the plans put in place during the first half of 2023. Primarily, to license our portfolio of NanoZolid developed products and secondly, to reduce costs giving the strategy sufficient time to be successful where possible. Fundamental for us has been the work with Alira Health to seek a partner for Liproca Depot. My objective as acting CEO since the summer has been to provide the stability and continuity to give these ambitions the best chance of success. However, as we move towards the end of the year, we must be realistic on the probability of success and be proactive on what comes next.

Over the last 18 months LIDDS has given business development the highest priority, where Alira Health have been a key partner in our search for a meaningful transaction for Liproca Depot in particular, but also the wider portfolio. This work has been aimed at demonstrating the commercial attractiveness of our lead asset as well as providing wider validation for the portfolio. Unfortunately, these efforts have coincided with the toughest market conditions seen in the Biotech space for many years.

Working with Alira has seen LIDDS reach out to over 200 companies over the last 12 months. Companies were selected for their specific interest in oncology and urology, incorporating the full spectrum of companies from multinational pharma companies to smaller specialist companies. As things stand today, most of the companies approached have so far declined the opportunity to license assets from LIDDS. We continue to work on the remaining options and keep channels of communication open for the future, but we must be realistic with our expectations for a major partner to license Liproca and the other assets. This is, of course, very disappointing, but we must learn from the exercise, be agile with the opportunities remaining, whilst also proactively working on alternative strategies for the assets and the business as a whole. These alternatives will be a major focus for LIDDS going forward.

The circumstances we are in validate the decisions taken in early summer to save costs and make the organisation leaner. Savings made will have full effect from 1 January 2024, which means that we now have a cash runway that is expected to extend into 2025. This is critical, as it gives the management and board time to consider a broad spectrum of opportunities and make well-considered decisions. Right now, nothing is off the table, we are committed to finding and increasing shareholder value wherever it can be found. This is a work already in progress. One example is our decision to find a path forward for the Nanodotax product and the DTX-002 clinical study. This was one of the activities that was put on hold earlier in the summer, but which we now have the ambition to restart in the new year, but at significantly lower cost to LIDDS. There is value in these assets, and while conditions are tough, we must continue to seek innovative ways to move the pipeline forward at every opportunity.

Finally, as we shape the business for 2024, we will do so with a revised management structure, further contributing to the savings and extending the cash runway. I took on the role as acting CEO during the summer with the ambition to provide continuity and stability at a turbulent time, and to complete the business objectives and processes that we had begun. As we complete those now, it is also time for me to move on to pastures new. I will leave LIDDS with some sadness, but I am very confident in my successor, Jenni Björnulfsson, as CEO. She has been with LIDDS since 2021 and knows the business very well. As we now consider all options for LIDDS, her experience and skillset are vital and valuable. I will remain with the business, at least until year end, and will support Jenni and the board in my role as CSO.

Matthew Lindon
CSO & Acting-CEO

The interim report is available on the company’s website https://liddspharma.com/en/investors/financial-reports/